A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer
The purpose of this study is to evaluate the safety and tolerability of BMS-986183 in patients with liver cancer.
Hepatocellular Carcinoma
BIOLOGICAL: BMS-986183|BIOLOGICAL: Nivolumab
Incidence of Adverse Events at Its Worst Grade, Evaluated by comparing the incidence of Adverse Events (AEs) among subjects using their assigned treatment for at least one day., First dose up to approximately 24 months|Incidence of Serious Adverse Events at Its Worst Grade, Evaluated by comparing the incidence of Serious Adverse Events (SAEs) among subjects using their assigned treatment for at least one day., First dose up to approximately 24 months|Incidence of Adverse Events Leading to Discontinuation, Evaluated by comparing the incidence of Adverse Events leading to discontinuation among subjects using their assigned treatment for at least one day., First dose up to approximately 24 months|Incidence of Adverse Events Leading to Death, Evaluated by comparing the incidence of Adverse Events leading to death among subjects using their assigned treatment for at least one day., First dose up to approximately 24 months|Incidence of Laboratory Test Toxicity Grade Shifting From Baseline, First dose up to approximately 24 months
Best Overall Response (BOR), Defined as BOR designation over the study as a whole, recorded between the dates of first dose until the last tumor assessment prior to subsequent therapy. CR or PR determinations included in the BOR assessment must be confirmed by a second scan performed no less than 4 weeks after the criteria for response are first met., First dose up to approximately 24 months|Overall Response Rate (ORR), Defined as the total number of subjects whose BOR is either a CR or PR divided by the total number of subjects in the population of interest, First dose up to approximately 24 months|Duration of Response (DoR), Defined as the time between the date of first response and the subsequent date of objectively documented disease progression or death, whichever occurs first. For those subjects who remain alive and have not progressed or received subsequent therapy, DoR will be censored on the date of last tumor assessment, First dose up to approximately 24 months|Progression Free Survival (PFS), Defined as the time from the first dose of study drug to the date of the first objective documentation of tumor progression or death due to any cause. Subjects who did not progress nor died will be censored on the date of their last tumor assessment. Subjects who did not have any on-study tumor assessments will be censored on the date of the first dose of study drug., First dose up to approximately 24 months|PFS Rate at Week 't', Defined as the proportion of subjects who remain progression free and surviving at 't' weeks (t=12, 24, 36, etc). The proportion will be calculated by the product-limit method (Kaplan-Meier \[K-M\] estimate) which takes into account censored data, First dose up to approximately 24 months|Maximum Observed Concentration (Cmax), To characterize the PK of the total antibody \[unconjugated antibody + antibody conjugated to tubulysin or antibody conjugated to any tubulysin metabolites\], active ADC \[antibody conjugated to tubulysin\], and unconjugated tubulysin) of BMS-986183 as monotherapy and in combination with nivolumab will be measured by Cmax, From first does up to approximately 24 months|Time of Maximum Observed Concentration (Tmax), to characterize the PK of the total antibody \[unconjugated antibody + antibody conjugated to tubulysin or antibody conjugated to any tubulysin metabolites\], active ADC \[antibody conjugated to tubulysin\], and unconjugated tubulysin) of BMS-986183 as monotherapy and in combination with nivolumab will be measured by Tmax., First dose up to approximately 24 months|Area Under the Concentration-time Curve From Time 0 to T of the Last Quantifiable Concentration [AUC(0-T)], to characterize the PK of the total antibody \[unconjugated antibody + antibody conjugated to tubulysin or antibody conjugated to any tubulysin metabolites\], active ADC \[antibody conjugated to tubulysin\], and unconjugated tubulysin) of BMS-986183 as monotherapy and in combination with nivolumab will be measured by AUC(0-T)\], First does up to appromimately 24 months|Area Under the Concentration-time Curve in 1 Dosing Interval [AUC(TAU)], To characterize the PK of the total antibody \[unconjugated antibody + antibody conjugated to tubulysin or antibody conjugated to any tubulysin metabolites\], active ADC \[antibody conjugated to tubulysin\], and unconjugated tubulysin) of BMS-986183 as monotherapy and in combination with nivolumab will be measured by AUC(TAU)., First dose up to approximately 24 months|Concentration at the End of a Dosing Interval (Ctau), To characterize the PK of the total antibody \[unconjugated antibody + antibody conjugated to tubulysin or antibody conjugated to any tubulysin metabolites\], active ADC \[antibody conjugated to tubulysin\], and unconjugated tubulysin) of BMS-986183 as monotherapy and in combination with nivolumab will be measured by, First dose up to approximately 24 months|Trough Observed Concentration, Including Predose Concentrations and Ctau (Ctrough), to characterize the PK of the total antibody \[unconjugated antibody + antibody conjugated to tubulysin or antibody conjugated to any tubulysin metabolites\], active ADC \[antibody conjugated to tubulysin\], and unconjugated tubulysin) of BMS-986183 as monotherapy and in combination with nivolumab will be measured by (Ctrough), First dose up to approximately 24 months|Total Body Clearance (CLT), to characterize the PK of the total antibody \[unconjugated antibody + antibody conjugated to tubulysin or antibody conjugated to any tubulysin metabolites\], active ADC \[antibody conjugated to tubulysin\], and unconjugated tubulysin) of BMS-986183 as monotherapy and in combination with nivolumab will be measured by CLT, First dose to approximately 24 months|Apparent Volume of Distribution at Steady-state (Vss), to characterize the PK of the total antibody \[unconjugated antibody + antibody conjugated to tubulysin or antibody conjugated to any tubulysin metabolites\], active ADC \[antibody conjugated to tubulysin\], and unconjugated tubulysin) of BMS-986183 as monotherapy and in combination with nivolumab will be measured by Vss, First dose up to approximately 24 months|Volume of Distribution of Terminal Phase (Vz), (to characterize the PK of the total antibody \[unconjugated antibody + antibody conjugated to tubulysin or antibody conjugated to any tubulysin metabolites\], active ADC \[antibody conjugated to tubulysin\], and unconjugated tubulysin) of BMS-986183 as monotherapy and in combination with nivolumab will be measured by Vz., First dose up to approximately 24 months|Accumulation Index; Ratio of Cmax at Steady-state to Cmax After the First Dose (AI_Cmax), to characterize the PK of the total antibody \[unconjugated antibody + antibody conjugated to tubulysin or antibody conjugated to any tubulysin metabolites\], active ADC \[antibody conjugated to tubulysin\], and unconjugated tubulysin) of BMS-986183 as monotherapy and in combination with nivolumab will be measured by AI_Cmax., First dose up to approximately 24 months|Accumulation Index; Ratio of Ctau at Steady-state to Ctau After the First Dose (AI_Ctau), to characterize the PK of the total antibody \[unconjugated antibody + antibody conjugated to tubulysin or antibody conjugated to any tubulysin metabolites\], active ADC \[antibody conjugated to tubulysin\], and unconjugated tubulysin) of BMS-986183 as monotherapy and in combination with nivolumab will be measured by AI_Ctau., First dose up to approximately 24 months|Accumulation Index; Ratio of AUC(TAU) at Steady-state to AUC(TAU) After the First Dose [AI_AUC(TAU)], To characterize the PK of the total antibody \[unconjugated antibody + antibody conjugated to tubulysin or antibody conjugated to any tubulysin metabolites\], active ADC \[antibody conjugated to tubulysin\], and unconjugated tubulysin) of BMS-986183 as monotherapy and in combination with nivolumab will be measured by AI_AUC(TAU)., First dose up to approximately 24 months|Average Concentration Over a Dosing Interval Calculated by Dividing AUC(TAU) at Steady State by Tau (Css,Ave), To characterize the PK of the total antibody \[unconjugated antibody + antibody conjugated to tubulysin or antibody conjugated to any tubulysin metabolites\], active ADC \[antibody conjugated to tubulysin\], and unconjugated tubulysin) of BMS-986183 as monotherapy and in combination with nivolumab will be measured by Css,avg., First dose up to approximately 24 months|Terminal Half-life (T-HALF), to characterize the PK of the total antibody \[unconjugated antibody + antibody conjugated to tubulysin or antibody conjugated to any tubulysin metabolites\], active ADC \[antibody conjugated to tubulysin\], and unconjugated tubulysin) of BMS-986183 as monotherapy and in combination with nivolumab will be measured by T-HALF., First dose up to approximately 24 months|Changes in QTcF (Î”QTcF) From Baseline, To assess the effect of dosage regimen and exposure \[active ADC and unconjugated tubulysin\] of BMS-986183 as monotherapy on the QT interval., Baseline up to approximately 24 months|Incidence of Positive Anti-drug Antibody (ADA), The immunogenicity of BMS-986183 (as monotherapy and in combination with nivolumab) will be measured by assessment of the presence or absence of specific ADA to BMS-986183. The incidence of positive ADA will be calculated., First dose up to approximately 24 months
The purpose of this study is to evaluate the safety and tolerability of BMS-986183 in patients with liver cancer.